Onyx Looking For Potential Suitors After Rejecting Amgen’s Bid

Onyx Looking For Potential Suitors After Rejecting Amgen’s Bid

Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) has become an acquisition target for many companies. The cancer drug maker has rejected an unsolicited acquisition offer of $120 per share from Amgen Inc. (NASDAQ:AMGN). Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) said in a statement that it is looking for potential suitors. It rejected Amgen Inc (NASDAQ:AMGN)’s offer because the bid significantly undervalued Onyx Pharmaceuticals Inc. (NASDAQ:ONXX).

Amgen Inc (NASDAQ:AMGN) was paying a 38 percent premium to its closing price on Friday, valuing the biotech company at $8.7 billion. Onyx Pharmaceuticals Inc. shares surged a record 51.3 percent to $131.33 on Monday.

OnyxWhy Amgen Targeted Onyx

The San Francisco-based Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) has three major drugs under its stable. It sells liver and kidney cancer drug Nexavar, and colon cancer drug Stivarga in collaboration with Bayer AG (OTCMKTS:BAYRY) (FRA:BAYN). Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) launched its third drug Krypolis last year, which analysts expect to generate $3 billion in annual sales. Onyx has also licensed its breast cancer drug palbociclib to Pfizer Inc. (NYSE:PFE), for which it gets 8 percent global royalty.

SALT New York: Wellington’s CEO On The Benefits Of Active Management

At this year's SALT New York conference, Jean Hynes, the CEO of Wellington Management, took to the stage to discuss the role of active management in today's investment environment. Hynes succeeded Brendan Swords as the CEO of Wellington at the end of June after nearly 30 years at the firm. Wellington is one of the Read More

Amgen Inc. (NASDAQ:AMGN) is trying to boost growth amid safety concerns that affected the sales of its anemia drug. Amgen Inc. (NASDAQ:AMGN) has five blockbuster drugs and patents on four of them will start expiring from 2015. Acquiring Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) could bolster its sales because Onyx products are yet to reach their sales peak.

Other Possible Bidders

After Onyx rejected Amgen Inc (NASDAQ:AMGN)’s offer, Soyoung Kim and Jessica Toonkel of Reuters reported that drug giants like Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS) could join the bidding war. Pfizer Inc. (NYSE:PFE) already has a partnership with Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) for palbociclib. Novartis AG (NYSE:NVS) has a strong presence in cancer market, and it may want to strengthen its position in the high margin business.

The other potential acquirer could be Bayer AG (OTCMKTS:BAYRY) (FRA:BAYN) which markets two of Onyx Pharmaceuticals Inc. (NASDAQ:ONXX)’s drugs.

JPMorgan analyst Cory Kasimov said in a research note to investors that the obvious bidders would be Bayer AG (OTCMKTS:BAYRY) (FRA:BAYN) and Pfizer Inc. (NYSE:PFE). JPMorgan also believes that any biopharmaceutical company that has a strong presence in oncology-hematology businesses could have a legitimate interest in Onyx Pharmaceuticals Inc (NASDAQ:ONXX). JPMorgan has an Overweight rating on the stock with $150 price target.

Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) shares were up 2.25 percent to $134.28 at 11:30 AM EDT.

Updated on

No posts to display